65
Participants
Start Date
February 29, 2012
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
QBX258
QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
Placebo
The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
Novartis Investigative Site, Berlin
Novartis Investigative Site, Winston-Salem
Novartis Investigative Site, Raleigh
Novartis Investigative Site, Spartanburg
Novartis Investigative Site, Aventura
Novartis Investigative Site, Minneapolis
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, St Louis
Novartis Investigative Site, Wiesbaden
Novartis Investigative Site, Oklahoma City
Novartis Investigative Site, Denver
Novartis Investigative Site, Denver
Novartis Investigative Site, Rolling Hills Estates
Novartis Investigative Site, San Marino
Novartis Investigative Site, Riverside
Novartis Investigative Site, Anaheim
Novartis Investigative Site, Boston
Novartis Investigative Site, Medford
Novartis Investigative Site, London
Novartis Investigative Site, Manchester
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY